Alector (ALEC) - Multiplikator Forward P/S
Alector, Inc. (ALEC) leads the field of immunoneurology, developing drugs to stimulate the brain's protective functions against neuronal degeneration. The company's modeled P/S visualizes market expectations, with the 1.60 value reflecting the metric's balance. The business targets the global market for Alzheimer's and Parkinson's treatments. Currently, Alector, Inc. (ALEC) is scaling its potential by conducting large-scale clinical trials of innovative therapeutic solutions.
Rincian analitis perusahaan Alector, Inc.
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Alector, Inc.|ALEC - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Alector|ALEC - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Alector, Inc.|ALEC - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Alector|Rasio cepet alector.com
- data bathi bisnis lan rasio investasi:
ALEC - Penghasilan resik|Bathi sing dikarepake Alector, Inc.|ALEC - Pangali rega marang bathi|Pangali Forward P/E Alector|ALEC - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Alector, Inc.|ALEC - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Alector|ALEC - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan alector.com|ALEC - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Alector, Inc.
- indikator dodolan lan pendapatan:
Analisis fundamental perusahaan:ALEC (Alector Therapeutics)
The resilience of Alector, Inc. (ALEC) is based on the synergy between management's scientific expertise and strategic partnerships in Alzheimer's disease therapy. When analyzing the forward P/S ratio, an investor correlates the current market capitalization with projected revenue to determine the cost of each dollar of expected sales. This metric allows for the identification of overvalued assets, preventing the acquisition of a business at the peak of unjustified expectations regarding clinical programs.
Karo sapa Alector, Inc. saingan
Biogen - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NBIX|Regencell - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Axsome Corp AXSM|ACADIA Pharmaceuticals (ACAD) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan XENE|VKTX (Viking Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Supernus Pharmaceuticals, Inc. (SUPN)|Multiplikator forward rega marang pendapatan CPRX (Catalyst Pharmaceuticals Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Denali Corp|Multiplikator Forward P/S HRMY (Harmony Biosciences)|Multiplikator Forward P/S biohavenpharma.com BHVN|AMLX - Rasio rega marang prakiraan pendapatan|TRVI: Rasio rega marang prakiraan pendapatan|PRAX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Anavex Life Sciences Corp (AVXL)|CBLL (CeriBell, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Prothena Corporation (PRTA)|Rasio rega marang prakiraan pendapatan Annexon (ANNX)|omeros.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|VYGR: Multiplikator forward rega marang pendapatan|NMRA - Multiplikator Forward P/S|Scilex (SCLX) - Rasio rega marang prakiraan pendapatan|Tevogen Bio Holdings Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alpha Cognition Inc|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cognition Therapeutics Inc. CGTX|Multiplikator Forward P/S IKT|Multiplikator Forward P/S cassavasciences.com (SAVA)|Rasio rega marang prakiraan pendapatan Assertio ASRT|Coya Therapeutics Inc - Rasio rega marang prakiraan pendapatan|VistaGen Therapeutics Inc - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ovid Therapeutics Inc.|ABOS: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan cervomed.com|Multiplikator forward rega marang pendapatan ATHE|CLNN (Clene Nanomedicine) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan PepGen Inc. (PEPG)|JUNS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Relmada Therapeutics RLMD|Rega forward marang dodolan ANVS|GRCE: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AIFF (Firefly Neuroscience, Inc.)|KLTO: Multiplikator Forward P/S|NRSN - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals|Kapitalisasi marang prakiraan pendapatan MTVA (MetaVia, Inc.)|Multiplikator Forward P/S NRXS|Multiplikator forward rega marang pendapatan heliusmedical.com HSDT|Passage Bio - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - Multiplikator Forward P/S|ATHA - Multiplikator Forward P/S|Addex Therapeutics Ltd (ADXN) - Rasio rega marang prakiraan pendapatan|ALZN (Alzamend Neuro) - Rasio rega marang prakiraan pendapatan|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Protagenic PTIX|Multiplikator Forward P/S KTTA|Multiplikator forward rega marang pendapatan cortigent.com CRGT|Rasio rega marang prakiraan pendapatan Avenue Therapeutics, Inc. ATXI|BCLI: Kapitalisasi marang prakiraan pendapatan|Cara Therapeutics, Inc - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chromocell|ELYM (eliemtx.com) - Multiplikator forward rega marang pendapatan|Intra-Cellular Therapies, Inc. (ITCI) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Longboard Pharmaceuticals, Inc.|MRNS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|NRBO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S SAGE (Sage Therapeutics, Inc.)|Multiplikator Forward P/S synaptogen.com SNPX|TRVN - Rasio rega marang prakiraan pendapatan|VIGL: Rasio rega marang prakiraan pendapatan|WENA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cerevel Corp (CERE)
